CytomX Therapeutics

Historical price data

CytomX Therapeutics is a clinical-stage oncology company leveraging its proprietary Probody® platform to develop conditionally activated therapeutics designed to minimize off-tumor toxicity. The company has built a diversified pipeline of eight candidates, including key clinical-stage assets like CX-904 (EGFRxCD3 T-cell engager) and CX-2051 (EpCAM ADC), supported by strategic partnerships with major pharmaceutical firms such as Amgen, AbbVie, and Bristol Myers Squibb. CytomX's strategy combines internal development of wholly-owned assets with a capital-efficient partnership model to validate and expand the application of its platform technology across multiple therapeutic modalities.

The Probody® platform is a conditional activation technology that creates antibody prodrugs designed to remain inert in healthy tissue and become activated specifically within the tumor microenvironment by disease-associated proteases.